Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Elsie Allen"'
Publikováno v:
Journal of Diabetes and its Complications. 28:887-893
Aims To examine whether concomitant statin therapy affects glycemic control with saxagliptin 2.5 and 5mg/d in patients with type 2 diabetes mellitus (T2DM). Methods Efficacy and safety were analyzed post hoc for pooled data from 9 saxagliptin randomi
Autor:
Raymond A. Harvey, Todd Prewitt, Brandon T. Suehs, Tony DeLuzio, Claudia Uribe, Elsie Allen, Ibrahim M Abbass, Jonathan Bouchard, Jenna Collins
Publikováno v:
Current medical research and opinion. 33(8)
Readmission is costly among patients with type 2 diabetes (T2DM) in Medicare Advantage Prescription Drug Plans; identifying high-risk patients is necessary for targeting reduction programs. The objective of this study was to develop a claims-based al
Publikováno v:
Postgraduate Medicine. 125:145-154
This post hoc analysis sought to assess the efficacy, safety, and tolerability of saxagliptin in patients with type 2 diabetes mellitus and cardiovascular (CV) risk factors or disease (CVD).Data from 5 randomized controlled trials were pooled to comp
Publikováno v:
Diabetes and Vascular Disease Research. 8:125-135
To assess the long-term efficacy and safety of saxagliptin in patients with type 2 diabetes mellitus inadequately controlled with thiazolidinedione monotherapy, 565 patients were randomised to saxagliptin (2.5 mg or 5 mg) or placebo added to thiazoli
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 94:4810-4819
Due to the natural progression of type 2 diabetes (T2D), most patients require combination therapy to maintain glycemic control.Our objective was to evaluate efficacy and safety of saxagliptin plus thiazolidinedione (TZD) in patients with T2D and ina
Autor:
Vishal Saundankar, Elsie Allen, Chad Moretz, Tony DeLuzio, Jonathan Bouchard, Yunus Meah, Brandon T. Suehs, Jeffrey J Ellis
Publikováno v:
Advances in therapy. 32(7)
Diabetes-related healthcare costs are increasing in the United States, with inpatient hospitalization the largest component of medical expenditures. The aims of this study were to characterize hospitalized type 2 diabetes mellitus (T2DM) patients, un
Autor:
Bruce W. Bode, Priscilla Hollander, Robert A. Gabbay, Philip Raskin, Andrew Lewin, Elsie Allen, Peter Hu, Alan M. Garber
Publikováno v:
Diabetes Care. 28:260-265
OBJECTIVE—Safety and efficacy of biphasic insulin aspart 70/30 (BIAsp 70/30, prebreakfast and presupper) were compared with once-daily insulin glargine in type 2 diabetic subjects inadequately controlled on oral antidiabetic drugs (OADs). RESEARCH
Publikováno v:
Diabetes Research and Clinical Practice. 66:23-29
Preprandial dosing (within 5 min before meal) and postprandial dosing (15-20 min after meal onset) of NovoLog Mix 70/30 (BIAsp 30, a biphasic formulation of insulin aspart, 30% soluble and 70% protamine-crystallized) were compared in elderly (> or =6
Autor:
Tony DeLuzio, Brandon T. Suehs, I.M. Abbass, Raymond A. Harvey, J.C. Collins, E. Kimball, Andrew Renda, C. Uribe, Elsie Allen, Jonathan Bouchard
Publikováno v:
Value in Health. 19:A7
Autor:
Neil Wintfeld, Elsie Allen, Brandon T. Suehs, Jonathan Bouchard, Antonio J Deluzio, Vishal Saundankar, Chad Moretz, Phil Schwab
Publikováno v:
BMJ Open Diabetes Research & Care
Background The study examined the prevalence of early treatment revisions after glycosylated hemoglobin (HbA1c) ≥9.0% (75 mmol/mol) and estimated the impact of early treatment revisions on glycemic control, diabetic complications, and costs. Resear